Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition, Lancet Neurol, vol.9, issue.4, pp.203-218, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00629750
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst, vol.11, issue.1, pp.30-46, 2006. ,
Advances in the diagnosis, pathogenesis and treatment of CIDP, Nat Rev Neurol, vol.7, issue.9, pp.507-524, 2011. ,
Chronic inflammatory demyelinating polyneuropathy, N Engl J Med, vol.352, issue.13, pp.1343-56, 2005. ,
Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5, Nat Immunol, vol.5, issue.9, pp.943-52, 2004. ,
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, vol.1, p.2062, 2015. ,
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, vol.12, p.3906, 2012. ,
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.1797, 2013. ,
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.3280, 2013. ,
Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis, Eur J Neurol, vol.18, issue.12, pp.1417-1438, 2011. ,
Autophagy in neuroinflammatory diseases, Autoimmun Rev, vol.16, issue.8, pp.856-74, 2017. ,
Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties, Bioconjug Chem, vol.21, issue.8, pp.1439-1486, 2010. ,
Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies, J Neuroimmunol, vol.278, pp.1-10, 2015. ,
The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J Biol Chem, vol.277, issue.24, pp.21453-21460, 2002. ,
FTY720: a most promising immunosuppressant modulating immune cell functions, J Biol Chem, vol.7, issue.8, pp.47408-47423, 2003. ,
,
, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing, J Immunol, vol.160, issue.10, pp.5037-5081, 1998.
The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors, FASEB J, vol.18, issue.3, pp.551-554, 2004. ,
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science, vol.296, issue.5566, pp.346-355, 2002. ,
Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis, Neurology, vol.76, issue.8, pp.20-27, 2011. ,
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis, Neurology, vol.71, issue.16, pp.1261-1268, 2008. ,
Oral fingolimod (FTY720) for relapsing multiple sclerosis, N Engl J Med, vol.355, issue.11, pp.1124-1164, 2006. ,
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617764
,
, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.6, pp.545-56, 2014.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617750
FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves, Exp Neurol, vol.210, issue.2, pp.681-90, 2008. ,
FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis, Neuropathol Appl Neurobiol, vol.35, issue.5, pp.487-95, 2009. ,
Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection, J Neuroinflammation, vol.14, issue.1, p.92, 2017. ,
Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy, J Neuroimmunol, vol.214, issue.1-2, pp.93-100, 2009. ,
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, Lancet Neurol, vol.17, issue.8, pp.689-98, 2018. ,
Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies, vol.6, 2017. ,
Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention, Acta Neuropathol, vol.130, issue.4, pp.445-68, 2015. ,
Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol, vol.46, issue.6, pp.910-913, 1999. ,
Incidence and prevalence of CIDP and the association of diabetes mellitus, vol.73, pp.39-45, 2009. ,
Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies, J Peripher Nerv Syst, vol.17, issue.2, pp.34-43, 2012. ,
Novel pathomechanisms in inflammatory neuropathies, J Neuroinflammation, vol.14, issue.1, p.232, 2017. ,
Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review, BMC Neurol, vol.14, p.26, 2014. ,
Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations, Autoimmune Dis, 2014. ,
Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan, Expert Rev Neurother, vol.17, issue.8, pp.755-65, 2017. ,
An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies, J Autoimmun, vol.92, pp.114-139, 2018. ,
Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy. Sci Rep, vol.8, p.5648, 2018. ,
,
FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, vol.9, issue.11, pp.883-97, 2010. ,
Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility, Mol Microbiol, vol.78, issue.5, pp.1130-1174, 2010. ,
Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models, J Neurosci Res, vol.91, issue.7, pp.871-81, 2013. ,
Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst, vol.15, issue.4, pp.345-56, 2010. ,
Fingolimod and CIDP: insights from negative results, Lancet Neurol, 2018. ,
Cellular and molecular aspects of myelin protein gene expression, Mol Neurobiol, vol.2, issue.1, pp.41-89, 1988. ,
Biology of oligodendrocyte and myelin in the mammalian central nervous system, Physiol Rev. avr, vol.81, issue.2, pp.871-927, 2001. ,
The prevalence of multiple sclerosis in the world: an update, Neurol Sci. avr, vol.22, issue.2, pp.117-156, 2001. ,
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research, Brain. août, vol.129, pp.1953-71, 2006. ,
Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis, Arch Immunol Ther Exp (Warsz), vol.58, issue.5, pp.325-358, 2010. ,
Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review, Neurochem Res. août, vol.19, issue.8, pp.935-979, 1994. ,
Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease, Clin Immunol Immunopathol. oct, vol.77, issue.1, pp.4-13, 1995. ,
Insights into the aetiology and pathogenesis of multiple sclerosis, Immunol Cell Biol. févr, vol.76, issue.1, pp.47-54, 1998. ,
The origin and application of experimental autoimmune encephalomyelitis, Nat Rev Immunol, vol.7, issue.11, pp.904-916, 2007. ,
Guillain-Barré syndrome, Lancet, vol.5, issue.9497, pp.1653-66, 2005. ,
Guillain-Barré syndrome, Neurol Sci. mars, vol.27, issue.1, pp.47-51, 2006. ,
Guillain-Barré syndrome: an update, J Clin Neurosci. juin, vol.16, issue.6, pp.733-774, 2009. ,
Progress in Guillain-Barré syndrome, Curr Opin Neurol, vol.14, issue.5, pp.597-604, 2001. ,
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system, Muscle Nerve. août, vol.30, issue.2, pp.131-56, 2004. ,
The Guillain-Barré syndrome: a true case of molecular mimicry, Trends Immunol. févr, vol.25, issue.2, pp.61-67, 2004. ,
The immunopathogenesis of Miller Fisher syndrome, J Neuroimmunol. déc, vol.100, issue.1-2, pp.3-12, 1999. ,
Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition, Lancet Neurol. avr, vol.9, issue.4, pp.402-414, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00629750
Chronic inflammatory polyradiculoneuropathy, Mayo Clin Proc. nov, vol.50, issue.11, pp.621-658, 1975. ,
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. mars, vol.11, issue.1, pp.30-46, 2006. ,
, Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), Neurology. mai, vol.41, issue.5, pp.617-625, 1991.
Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol Neurosurg Psychiatry. févr, vol.79, issue.2, pp.115-123, 2008. ,
Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. janv, vol.25, issue.1, pp.26-30, 2002. ,
, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision, Joint Task Force of the EFNS and the PNS, vol.15, pp.1-9, 2010.
Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients, J Neurol Neurosurg Psychiatry. juill, vol.61, issue.1, pp.36-42, 1996. ,
, Rev Neurol (Paris), vol.148, issue.12, pp.752-61, 1992.
A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. mars, vol.15, issue.1, pp.50-56, 2010. ,
Variable and recurrent ptosis and ophthalmoplegia in chronic polyradiculoneuritis, Rev Neurol (Paris). avr, vol.153, issue.3, pp.197-200, 1997. ,
Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies, Clin Neurophysiol. mars, vol.112, issue.3, pp.457-63, 2001. ,
Transcranial magnetic stimulation in lower motor neuron diseases, Clin Neurophysiol. janv, vol.116, issue.1, pp.35-42, 2005. ,
Multifocal demyelinating neuropathy with persistent conduction block, Neurology. sept, vol.32, issue.9, pp.958-64, 1982. ,
Peripheral neuropathies and anti-glycolipid antibodies, Brain. déc, vol.125, pp.2591-625, 2002. ,
Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy, J Neurol Neurosurg Psychiatry. janv, vol.81, issue.1, pp.61-65, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00552791
Magnetic stimulation using a triplestimulation technique in patients with multifocal neuropathy without conduction block, Muscle Nerve. déc, vol.32, issue.6, pp.710-714, 2005. ,
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.1797, 2013. ,
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment, Ann Neurol. févr, vol.11, issue.2, pp.136-177, 1982. ,
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev. 25 août, issue.8, p.3906, 2015. ,
Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81, J Neuropathol Exp Neurol. mars, vol.57, issue.3, pp.291-301, 1998. ,
P0 glycoprotein peptides 56-71 and 180-199 dose-dependently induce acute and chronic experimental autoimmune neuritis in Lewis rats associated with epitope spreading, J Neuroimmunol. 1 mars, vol.114, issue.1-2, pp.99-106, 2001. ,
Induction of experimental autoimmune neuritis with peripheral myelin protein-22, Brain. oct, vol.121, pp.1895-902, 1998. ,
Animal models of immune-mediated neuropathies, Curr Opin Neurol, vol.15, issue.5, pp.617-639, 2002. ,
P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice, J Neurosci Res. 1 déc, vol.62, issue.5, pp.717-738, 2000. ,
Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12, J Neuroimmunol. 10 juill, vol.107, issue.1, pp.1-7, 2000. ,
Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside, Ann Neurol. juin, vol.49, issue.6, pp.712-732, 2001. ,
Various immunization protocols for an acute motor axonal neuropathy rabbit model compared, Neurosci Lett. 16 sept, vol.368, issue.1, pp.63-70, 2004. ,
Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines, Brain. févr, vol.114, pp.429-471, 1991. ,
Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigenspecific tolerization, J Neurosci Res. 15 févr, vol.75, issue.4, pp.524-559, 2004. ,
Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice, J Exp Med. 3 sept, vol.194, issue.5, pp.677-84, 2001. ,
Proteolipid protein (PLP) of CNS myelin: positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implications for the membrane topology of PLP, Biochemistry. 15 déc, vol.31, issue.49, pp.12289-96, 1992. ,
Thiopalmitoylation of myelin proteolipid protein epitopes enhances immunogenicity and encephalitogenicity, J Immunol. 1 juin, vol.166, issue.11, pp.6907-6920, 2001. ,
Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigenpresenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity, J Immunol. 1 févr, vol.180, issue.3, pp.1398-404, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00351007
Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties, Bioconjug Chem. 18 août, vol.21, issue.8, pp.1439-1486, 2010. ,
Charcot-Marie-Tooth disease: an update, Curr Opin Neurol, vol.17, issue.5, pp.579-85, 2004. ,
FTY720 (fingolimod) for relapsing multiple sclerosis, Expert Rev Neurother. mai, vol.8, issue.5, pp.699-714, 2008. ,
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis, Clin Neuropharmacol. avr, vol.33, issue.2, pp.91-101, 2010. ,
, , 2018.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity, J Neurochem. mars, vol.136, issue.5, pp.971-80, 2016. ,
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis, Br J Pharmacol. févr, vol.165, issue.4, pp.861-870, 2012. ,
, ClinicalTrials.gov. FORCIDP, ClinicalTrials.gov Identifier NCT01625182
Chronic inflammatory demyelinating polyradiculoneuropathy, Presse Med. juin, vol.42, issue.6, pp.203-215, 2013. ,
Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. avr, vol.29, issue.4, pp.565-74, 2004. ,
Chronic inflammatory demyelinating polyneuropathy, N Engl J Med. 31 mars, vol.352, issue.13, pp.1343-56, 2005. ,
Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. août, vol.38, issue.2, pp.1036-1081, 2008. ,
Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases, Ultrastruct Pathol. déc, vol.24, issue.6, pp.363-372, 2000. ,
Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP, Neurology. 27 déc, vol.65, issue.12, pp.1924-1933, 2005. ,
Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. déc, vol.15, issue.4, pp.345-56, 2010. ,
FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis, Neuropathol Appl Neurobiol, vol.35, issue.5, pp.487-95, 2009. ,
Th2 shift in mononeuritis multiplex and increase of Th2 cells in chronic inflammatory demyelinating polyneuropathy: an intracellular cytokine analysis, J Neurol Sci. 15 déc, vol.193, issue.1, pp.49-52, 2001. ,
pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. juin, vol.14, issue.2, pp.107-124, 2009. ,
Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients, Neurol Res, vol.34, issue.9, pp.842-848, 2012. ,
Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients, Ann Neurol. juin, vol.47, issue.6, pp.765-75, 2000. ,
Advances in the diagnosis, pathogenesis and treatment of CIDP, Nat Rev Neurol. 16 août, vol.7, issue.9, pp.507-524, 2011. ,
Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention, Acta Neuropathol, vol.130, issue.4, pp.445-68, 2015. ,
Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies, J Peripher Nerv Syst. mai, vol.17, issue.2, pp.34-43, 2012. ,
Novel pathomechanisms in inflammatory neuropathies, J Neuroinflammation, vol.14, issue.1, p.232, 2017. ,
Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review, BMC Neurol. 7 févr, vol.14, p.26, 2014. ,
Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations, Autoimmune Dis, 2014. ,
An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies, J Autoimmun. août, vol.92, pp.114-139, 2018. ,
Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy, J Neuroimmunol. 29 sept, vol.214, issue.1-2, pp.93-100, 2009. ,
Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy, vol.8, p.5648, 2018. ,
FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves, Exp Neurol. avr, vol.210, issue.2, pp.681-90, 2008. ,
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science. 12 avr, vol.296, issue.5566, pp.346-355, 2002. ,
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, vol.9, issue.11, pp.883-97, 2010. ,
Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility, Mol Microbiol. déc, vol.78, issue.5, pp.1130-1174, 2010. ,
Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models, J Neurosci Res. juill, vol.91, issue.7, pp.871-81, 2013. ,
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, Lancet Neurol. août, vol.17, issue.8, pp.689-98, 2018. ,
Fingolimod and CIDP: insights from negative results, Liste des communications orales et par affiche, vol.17, pp.655-661, 2018. ,
, Annexe 2 : Poster JNLF 2014 : Validation et caractérisation d'un modèle animal de polyradiculonévrite chronique
, Characterization of a new animal mode of chronic inflammatory demyelinating polyneuropathy, vol.3, 2014.
, Poster JNLF 2015 : Effet du FTY720 (Fingolimod) chez un nouveau modèle animal préclinique de polyradiculonévrite inflammatoire démyélinisante chronique, vol.4
,
Validation et caractérisation d'un modèle animal de polyradiculonévrite chronique, 2014. ,
,
Characterization of a new animal mode of chronic inflammatory demyelinating polyneuropathy, 2014. ,
,
, , 2015.
, Effet du FTY720 (Fingolimod) chez un nouveau modèle animal préclinique de polyradiculonévrite inflammatoire démyélinisante chronique
, J. de Seze ANNEXE, vol.5
, Effect of FTY720 (Fingolimod) in a new preclinical rat model for chronic inflammatory demyelinating polyneuropathy (CIDP), 2015.
,